Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim with this study is to investigate the effect of statin induced changes in HDL-C on all cause mortality and CVD with adjustment for changes in other blood lipids and clinical parameters in Sweden, UK and the Netherlands.
An observational study of statin treatment induced HDL changes - effect on cardiovascular disease
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Time to first occurrence of hospitalization for acute myocardial infarction, unstable angina pectoris or ischemic stroke related to changes in HDL-C | 1st of January 2004 to 31st December 2010 |
| Measure | Description | Time Frame |
|---|---|---|
| The effect of statin induced changes in HDL-C (per mmol/L) on a composite endpoint including unstable angina pectoris, myocardial infarction, ischemic stroke and all cause mortality. | 1st of January 2004 to 31st December 2010 | |
| Time to first occurence of hospitalization for acute myocardial infarction, unstable angina pectoris or ischemic stroke and ischemic heart disease mortality related to changes in HDL-C. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients who received a first prescription of a statin (ATC code C10AA) between 1st of January 2004 and 31st of December 2010. Swedish data will be extracted from medical records and national registers and for UK and the Netherlands from central registers.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gunnar Johansson, MD, PROFESSOR | Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology Uppsala University 751 22 Uppsala Sweden | Principal Investigator |
| Ron Herings, DR, ASSOC PROF | Pharmo Institute for Drug Outcomes Research3508 AE UtrechtThe Netherlands | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cholesterol values (HDL-C, LDL-C, TC)
| 1st of January 2004 to 31st December 2010 |
| The relationships between acquired HDL levels after statin treatment on the primary endpoint and the effect of HDL increase on the primary endpoint for different levels of baseline HDL | 1st of January 2004 to 31st December 2010 |
| Potential interactions between baseline HDL and HDL increase and other factors like age, gender, treatment and co-morbidity on the primary endpoint | 1st of January 2004 to 31st December 2010 |
| The health economic consequences of increasing HDL-C with statin treatment | 1st of January 2004 to 31st December 2010 |